CoChat

CCR6 is expressed on an IL-10–producing, autoreactive memory T cell population with context-dependent regulatory function

Open access

The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.

Abstract

Interleukin (IL)-10 produced by regulatory T cell subsets is important for the prevention of autoimmunity and immunopathology, but little is known about the phenotype and function of IL-10–producing memory T cells. Human CD4+CCR6+ memory T cells contained comparable numbers of IL-17– and IL-10–producing cells, and CCR6 was induced under both Th17-promoting conditions and upon tolerogenic T cell priming with transforming growth factor (TGF)–β. In normal human spleens, the majority of CCR6+ memory T cells were in the close vicinity of CCR6+ myeloid dendritic cells (mDCs), and strikingly, some of them were secreting IL-10 in situ. Furthermore, CCR6+ memory T cells produced suppressive IL-10 but not IL-2 upon stimulation with autologous immature mDCs ex vivo, and secreted IL-10 efficiently in response to suboptimal T cell receptor (TCR) stimulation with anti-CD3 antibodies. However, optimal TCR stimulation of CCR6+ T cells induced expression of IL-2, interferon-γ, CCL20, and CD40L, and autoreactive CCR6+ T cell lines responded to various recall antigens. Notably, we isolated autoreactive CCR6+ T cell clones with context-dependent behavior that produced IL-10 with autologous mDCs alone, but that secreted IL-2 and proliferated upon stimulation with tetanus toxoid. We propose the novel concept that a population of memory T cells, which is fully equipped to participate in secondary immune responses upon recognition of a relevant recall antigen, contributes to the maintenance of tolerance under steady-state conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20091021

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. CCR6 is induced by TGF-β and expressed on populations of CD25+ T reg cells and CD4+ memory T cells. (a) CFSE-labeled peripheral blood naive CD4+ T cells were stimulated with anti-CD3 and anti-CD28 antibodies for 4 d in the presence or absence of the indicated cytokines. Cells were stained at day 5, and CFSE− cells were analyzed for CCR6 and FOXP3 expression by flow cytometry. (b) Peripheral blood CD4+ T cell populations were analyzed for CCR6 and FOXP3 expression by flow cytometry ex vivo. Numbers indicate percentages. (c) Peripheral blood CD4+CD45RA−CD25− memory T cells were stained with antibodies specific for CCR6, IL-7Rα, CCR7, CLA, CXCR5, and integrin β7 and αE, and were analyzed by flow cytometry. The mean percentage of CCR6+ or CCR6− cells expressing the relevant surface marker of three different donors is shown.
Figure 1. CCR6 is induced by TGF-β and expressed on populations of CD25+ T reg cells and CD4+ memory T cells. (a) CFSE-labeled peripheral blood naive CD4+ T cells were stimulated with anti-CD3 and anti-CD28 antibodies for 4 d in the presence or absence of the indicated cytokines. Cells were stained at day 5, and CFSE− cells were analyzed for CCR6 and FOXP3 expression by flow cytometry. (b) Peripheral blood CD4+ T cell populations were analyzed for CCR6 and FOXP3 expression by flow cytometry ex vivo. Numbers indicate percentages. (c) Peripheral blood CD4+CD45RA−CD25− memory T cells were stained with antibodies specific for CCR6, IL-7Rα, CCR7, CLA, CXCR5, and integrin β7 and αE, and were analyzed by flow cytometry. The mean percentage of CCR6+ or CCR6− cells expressing the relevant surface marker of three different donors is shown.CC BY-NC-SA · PubMed Central
Figure 2. Ex vivo cytokine production of CCR6+ and CCR6− memory T cells after weak or strong TCR stimulation. (a) Up-regulation of CD69 and CD40L after stimulation of total antigen-experienced Th cells (CD45RA−CD25−) with anti-CD3 alone (left) or anti-CD3 plus anti-CD28 (right). One experiment out of three is shown. (b) Production of IL-10 versus IL-2 (left) or versus IFN-γ (right) at 6 (top) and 30 (bottom) h after stimulation with anti-CD3 alone or anti-CD3 plus anti-CD28. One representative experiment out of eight is shown. (c) Expression of CCL20 and IL-10 (left) or IL-17 (right) of CCR6+ and CCR6− memory T cells (IL-7R+CD25−CD45RA−) after stimulation with anti-CD3 antibodies in the absence or presence of CD28 co-stimulation. Two representative donors out of six analyzed in three independent experiments are shown. Numbers indicate percentages.
Figure 2. Ex vivo cytokine production of CCR6+ and CCR6− memory T cells after weak or strong TCR stimulation. (a) Up-regulation of CD69 and CD40L after stimulation of total antigen-experienced Th cells (CD45RA−CD25−) with anti-CD3 alone (left) or anti-CD3 plus anti-CD28 (right). One experiment out of three is shown. (b) Production of IL-10 versus IL-2 (left) or versus IFN-γ (right) at 6 (top) and 30 (bottom) h after stimulation with anti-CD3 alone or anti-CD3 plus anti-CD28. One representative experiment out of eight is shown. (c) Expression of CCL20 and IL-10 (left) or IL-17 (right) of CCR6+ and CCR6− memory T cells (IL-7R+CD25−CD45RA−) after stimulation with anti-CD3 antibodies in the absence or presence of CD28 co-stimulation. Two representative donors out of six analyzed in three independent experiments are shown. Numbers indicate percentages.CC BY-NC-SA · PubMed Central
Figure 3. CCR6+ memory T cells proliferate with autologous DCs upon IL-10 neutralization. (a) Purified CCR6+ and CCR6− T cells were incubated with ex vivo–isolated autologous or allogenic mDCs in the presence or absence of neutralizing anti–IL-10 antibodies. On day 7, CFSE profiles of T cells were analyzed by flow cytometry. One experiment out of six is shown. Numbers indicate percentages. (b) CCR6+ T cells and autologous mDCs were purified after 24 h following co-culture or culture in medium alone. IL-10 mRNA levels relative to 18S rRNA were quantified by quantitative real-time RT-PCR. Results are expressed in arbitrary units (AU) of IL-10 mRNA/18S rRNA. Error bars represent means of three different experiments analyzing different donors. (c) CCR6+ T cells were co-cultured with autologous or allogenic mDCs, and culture supernatants were assessed by ELISA for the presence of IL-2 and IL-10. The mean of three independent experiments is shown.
Figure 3. CCR6+ memory T cells proliferate with autologous DCs upon IL-10 neutralization. (a) Purified CCR6+ and CCR6− T cells were incubated with ex vivo–isolated autologous or allogenic mDCs in the presence or absence of neutralizing anti–IL-10 antibodies. On day 7, CFSE profiles of T cells were analyzed by flow cytometry. One experiment out of six is shown. Numbers indicate percentages. (b) CCR6+ T cells and autologous mDCs were purified after 24 h following co-culture or culture in medium alone. IL-10 mRNA levels relative to 18S rRNA were quantified by quantitative real-time RT-PCR. Results are expressed in arbitrary units (AU) of IL-10 mRNA/18S rRNA. Error bars represent means of three different experiments analyzing different donors. (c) CCR6+ T cells were co-cultured with autologous or allogenic mDCs, and culture supernatants were assessed by ELISA for the presence of IL-2 and IL-10. The mean of three independent experiments is shown.CC BY-NC-SA · PubMed Central
Figure 4. Immature mDCs most efficiently induce autoreactive T cell proliferation. (a) Purified, CFSE-labeled CCR6+ memory T cells were cultured with autologous or allogenic immature or LPS-matured mDCs in the presence of neutralizing anti–IL-10 antibodies, and proliferation was assessed on day 7. One experiment out of three is shown. (b) AIRE mRNA expression in purified monocytes, or immature or LPS-matured mDCs was measured by quantitative RT-PCR and normalized on 18S rRNA. AIRE expression in immature mDCs was set to 100%. The mean of three independent experiments is shown. (c) Purified blood monocytes, pDCs, and mDCs were stained for CCR6 surface expression in three healthy donors. Numbers indicate percentages.
Figure 4. Immature mDCs most efficiently induce autoreactive T cell proliferation. (a) Purified, CFSE-labeled CCR6+ memory T cells were cultured with autologous or allogenic immature or LPS-matured mDCs in the presence of neutralizing anti–IL-10 antibodies, and proliferation was assessed on day 7. One experiment out of three is shown. (b) AIRE mRNA expression in purified monocytes, or immature or LPS-matured mDCs was measured by quantitative RT-PCR and normalized on 18S rRNA. AIRE expression in immature mDCs was set to 100%. The mean of three independent experiments is shown. (c) Purified blood monocytes, pDCs, and mDCs were stained for CCR6 surface expression in three healthy donors. Numbers indicate percentages.CC BY-NC-SA · PubMed Central
Figure 5. CCR6+ T cells colocalize with CD11c+ DCs and produce IL-10 in the human spleen. (top) Spleen sections showing anti-CCR6–labeled CCR6+ cells (red) in the anti-CD3–stained (green) T cell areas and B cell follicles with a proportion of CCR6/CD3 double-positive cells (arrows). (bottom left) Double immunohistochemical staining displays the distribution of CD11c+ DCs (red) predominantly in the periarteriolar CD3+ (brown) T cell areas (T) but also in the red pulp (RP) and the marginal zone (MZ) of the B cell follicles (B). CCR6+ cells (red) in the T cell areas are often found close to CD11c+ DCs (brown; inset, CCR6 CD11c). (middle right) Within the periarteriolar T cell area, scattered IL-10+ cells (brown) can be identified, and costaining with anti-CD11c (red) indicates that some are in close contact to DCs (inset, IL-10 CD11c), whereas the large majority of IL-10+ cells were negative for FOXP3 (red, nuclear; inset, FOXP3 IL-10). (bottom right) Immunofluorescence shows that proportions of CD3+ or CCR6+ cells (green) coexpress IL-10 (red), resulting in a yellow overlay (merge). Stainings are representative of five samples each, and the cell numbers are summarized in Table I. Bars: (top; and bottom left) 100 µm; (middle right) 50 µm; (bottom right) 10 µm.
Figure 5. CCR6+ T cells colocalize with CD11c+ DCs and produce IL-10 in the human spleen. (top) Spleen sections showing anti-CCR6–labeled CCR6+ cells (red) in the anti-CD3–stained (green) T cell areas and B cell follicles with a proportion of CCR6/CD3 double-positive cells (arrows). (bottom left) Double immunohistochemical staining displays the distribution of CD11c+ DCs (red) predominantly in the periarteriolar CD3+ (brown) T cell areas (T) but also in the red pulp (RP) and the marginal zone (MZ) of the B cell follicles (B). CCR6+ cells (red) in the T cell areas are often found close to CD11c+ DCs (brown; inset, CCR6 CD11c). (middle right) Within the periarteriolar T cell area, scattered IL-10+ cells (brown) can be identified, and costaining with anti-CD11c (red) indicates that some are in close contact to DCs (inset, IL-10 CD11c), whereas the large majority of IL-10+ cells were negative for FOXP3 (red, nuclear; inset, FOXP3 IL-10). (bottom right) Immunofluorescence shows that proportions of CD3+ or CCR6+ cells (green) coexpress IL-10 (red), resulting in a yellow overlay (merge). Stainings are representative of five samples each, and the cell numbers are summarized in Table I. Bars: (top; and bottom left) 100 µm; (middle right) 50 µm; (bottom right) 10 µm.CC BY-NC-SA · PubMed Central
Figure 6. CCR6+ T cells respond to self- and recall antigens in healthy donors. (a) Sorted CFSE-labeled CCR6+ and CCR6− T cells from healthy individuals were cultured with autologous monocytes with or without MelanA or TT. CFSE profiles of CD3+CD14− cells were analyzed on day 7 by flow cytometry. One representative donor out of eight analyzed in independent experiments is shown. (b) Percentage of proliferating (CFSElo) CCR6+ and CCR6− T cells in eight healthy donors and six vitiligo patients. Horizontal bars indicate the mean percentages. (c) Autoreactive T cell lines were generated by stimulating CCR6+ T cells with autologous mDCs plus anti–IL-10 and sorting of cells that had lost CFSE on day 7. Cells were then incubated with autologous monocytes with or without MelanA, TT, or other recall antigens for 24 h in the presence of brefeldin A, and intracellular staining of cytokines was detected with specific antibodies (Table II). Forward scatter (FSC) and staining for IL-2 of autoreactive cells of one donor are shown. Numbers indicate percentages.
Figure 6. CCR6+ T cells respond to self- and recall antigens in healthy donors. (a) Sorted CFSE-labeled CCR6+ and CCR6− T cells from healthy individuals were cultured with autologous monocytes with or without MelanA or TT. CFSE profiles of CD3+CD14− cells were analyzed on day 7 by flow cytometry. One representative donor out of eight analyzed in independent experiments is shown. (b) Percentage of proliferating (CFSElo) CCR6+ and CCR6− T cells in eight healthy donors and six vitiligo patients. Horizontal bars indicate the mean percentages. (c) Autoreactive T cell lines were generated by stimulating CCR6+ T cells with autologous mDCs plus anti–IL-10 and sorting of cells that had lost CFSE on day 7. Cells were then incubated with autologous monocytes with or without MelanA, TT, or other recall antigens for 24 h in the presence of brefeldin A, and intracellular staining of cytokines was detected with specific antibodies (Table II). Forward scatter (FSC) and staining for IL-2 of autoreactive cells of one donor are shown. Numbers indicate percentages.CC BY-NC-SA · PubMed Central
Figure 7. Autoreactive CCR6+ T cell clones produce IL-2 with recall antigens. Clones were generated by expanding single cells from CCR6+ autoreactive T cell lines or from CCR6− TT-specific control lines and screened for tetanus specificity by [3H]thymidine incorporation after stimulation with TT. (a) Culture supernatants of TT-specific clones were assessed for the presence of IL-2, IFN-γ, and IL-10 by ELISA. Shown are concentrations of IL-10, IFN-γ, and IL-2 produced by three different autoreactive CCR6+ clones (gray bars, A–C) and two different CCR6− control clones (black bars, D and E) derived from the same two donors. (b) Proliferation measured by [3H]thymidine incorporation of CCR6+ (A and B) and CCR6− (E) TT-specific clones derived from the same donor in response to autologous monocytes (left) in the absence (open bars) or presence (shaded bars) of TT, and to autologous mDCs (right) with (shaded bars) or without (open bars) IL-10 neutralization. (c) Production of IL-2 (black lines) and IL-10 (red lines) of the same two CCR6+ TT-specific T cell clones (A and B; continuous and dotted lines, respectively) in response to different concentrations of anti-CD3 antibodies in the presence of CD28 co-stimulation.
Figure 7. Autoreactive CCR6+ T cell clones produce IL-2 with recall antigens. Clones were generated by expanding single cells from CCR6+ autoreactive T cell lines or from CCR6− TT-specific control lines and screened for tetanus specificity by [3H]thymidine incorporation after stimulation with TT. (a) Culture supernatants of TT-specific clones were assessed for the presence of IL-2, IFN-γ, and IL-10 by ELISA. Shown are concentrations of IL-10, IFN-γ, and IL-2 produced by three different autoreactive CCR6+ clones (gray bars, A–C) and two different CCR6− control clones (black bars, D and E) derived from the same two donors. (b) Proliferation measured by [3H]thymidine incorporation of CCR6+ (A and B) and CCR6− (E) TT-specific clones derived from the same donor in response to autologous monocytes (left) in the absence (open bars) or presence (shaded bars) of TT, and to autologous mDCs (right) with (shaded bars) or without (open bars) IL-10 neutralization. (c) Production of IL-2 (black lines) and IL-10 (red lines) of the same two CCR6+ TT-specific T cell clones (A and B; continuous and dotted lines, respectively) in response to different concentrations of anti-CD3 antibodies in the presence of CD28 co-stimulation.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

Metadata

Authors
Rivino, L., Gruarin, P., Häringer, B., Steinfelder, S., Lozza, L., Steckel, B., Weick, A., Sugliano, E., Jarrossay, D., Kühl, A. A., Loddenkemper, C., Abrignani, S., Sallusto, F., Lanzavecchia, A., & Geginat, J.
Affiliations
  • German Rheumatism Research Centre (DE)
  • Istituto Nazionale Genetica Molecolare (IT)
  • Institute for Research in Biomedicine (CH)
  • Charité – Universitätsmedizin Berlin (DE)
  • Technical University of Munich (DE)
Corresponding author
Geginat, Jens
Venue
Journal of Experimental Medicine
Published
2010-03-01
Volume
207
Issue
3
Pages
565-577
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2157480023
Cited by
64
References
60
Citations by year
2026: 1 · 2024: 2 · 2023: 6 · 2022: 1 · 2021: 3 · 2020: 7 · 2019: 2 · 2018: 4 · 2017: 4 · 2016: 2 · 2015: 7 · 2014: 7 · 2013: 4 · 2012: 4
FWCI
2.47
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion)
  • reroDoc Digital Library (submittedVersion)
  • National University of Singapore (submittedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • Explore Bristol Research (submittedVersion)
  • Bristol Research (University of Bristol) (submittedVersion)
Funders
Deutsche Forschungsgemeinschaft (SFB 650)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CCR6, IL-10, memory T cells, regulatory T cells, autoreactive T cells, Th17 cells, dendritic cells, T cell tolerance, T cell receptor stimulation, interleukin-2, CCL20, CD40 ligand, interferon-gamma, tetanus toxoid, autoimmunity
MeSH terms
Gene Expression Regulation, Homeostasis, Humans, Immunologic Memory, Immunosuppression Therapy, Interferon-gamma, Interleukin-2, Receptors, Antigen, T-Cell, T-Lymphocytes, CD4-Positive T-Lymphocytes, Transforming Growth Factor beta, Interleukin-10, T-Lymphocytes, Regulatory, Receptors, CCR6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.